Injection Site Reaction to Extended-Release Buprenorphine (Sublocade®) for Opioid Use Disorder Fourteen Days after Administration

Authors

  • Elizabeth Weesner School of Medicine, University of Kansas Medical Center, Kansas City, Kansas.
  • Hosain Ghassemi School of Medicine, University of Kansas Medical Center, Kansas City, Kansas.
  • Iryna Salapenka, M.D. 1Department of Psychiatry and Behavioral Sciences, University of Kansas Health System, Kansas City, Kansas.
  • Jaya Sri Konakanchi, MBBS School of Medicine, University of Kansas Medical Center, Kansas City, Kansas.
  • Gregory Maggio, D.O. 1Department of Psychiatry and Behavioral Sciences, University of Kansas Medical Center, Kansas City, Kansas
  • Roopa Sethi, M.D. Assistant Professor

DOI:

https://doi.org/10.17161/kjm.vol15.17931

Keywords:

Sublocade, Medication for Opioid Use Disorder (MOUD), Buprenorphine, side effect, cellulitis, injection

Metrics

Metrics Loading ...

Downloads

Published

2022-08-22

Issue

Vol. 15 No. 2 (2022): May - Aug.

Section

Case Reports

License

Copyright (c) 2022 Elizabeth Weesner, Hosain Ghassemi, Iryna Salapenka, M.D., Jaya Sri Konakanchi, MBBS, Gregory Maggio, D.O., Roopa Sethi, M.D.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

All articles in the Kansas Journal of Medicine are licensed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License (CC-BY-NC-ND 4.0). 

 

How to Cite

Elizabeth Weesner, Hosain Ghassemi, Iryna Salapenka, Jaya Sri Konakanchi, Gregory Maggio, & Sethi, R. (2022). Injection Site Reaction to Extended-Release Buprenorphine (Sublocade®) for Opioid Use Disorder Fourteen Days after Administration. Kansas Journal of Medicine, 15(2), 302-304. https://doi.org/10.17161/kjm.vol15.17931